Aura Biosciences Inc (AURA)
NASDAQ:AURA
Want to see AURA full AI Analyst Report?
AURA Stock Chart & Stats
$7.29
-$0.11(-1.36%)
At close: 4:00 PM EST
$7.29
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$4.73 - $9.54
Previous CloseN/A
Volume82.15K
Average Volume (3M)665.77K
Market Cap
$713.37M
Enterprise Value$411.77M
Total Cash (Recent Filing)$114.73M
Total Debt (Recent Filing)$16.99M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding103,386,560
10 Day Avg. Volume504,345
30 Day Avg. Volume665,767
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-717.37
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$19.75Price Target Upside170.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Funding RunwayA large $280.8M net equity raise materially extends Aura’s runway into H2 2028, reducing near-term financing risk. This durable capital buffer supports completion of Phase 3, registration-enabling work and program expansion, allowing management to execute without immediate dilution pressure.
Clear Late-stage Clinical MilestonesNear-term, well-defined milestones (enrollment by mid-2026, topline H2 2027) provide a predictable development timeline. Successful execution would convert a clinical program into a registrational asset, changing revenue prospects and strategic optionality long-term.
Low Leverage Vs EquityModest debt relative to equity gives balance-sheet flexibility during late-stage R&D. Lower leverage reduces bankruptcy and refinancing risk, allowing the company to prioritize clinical spend and strategic investments without heavy interest burdens.
Bears Say
No Revenue GenerationAura remains pre-commercial with zero revenue, meaning value is entirely dependent on trial outcomes and future commercialization. Lack of product income makes the company reliant on external funding and magnifies the impact of any clinical setbacks on long-term viability.
Persistent And Growing Cash BurnOperating and free cash flows are deeply negative and worsening, driving ongoing funding needs. Even with recent proceeds, sustained burn requires disciplined capital allocation or further financing, constraining strategic flexibility and increasing dilution risk over time.
High Clinical And Regulatory Execution RiskAs a development-stage biotech, Aura’s long-term prospects hinge on trial outcomes and regulatory approvals. Clinical failures or regulatory delays would materially impair commercialization potential and could erode the recent funding advantage, making program diversification riskier.
Aura Biosciences Inc News
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $4.73 and its highest was $9.54 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $713.37M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on May 11, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.398 by -$0.102.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -0.38.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 103,386,560 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.398. Following the earnings report the stock price went down -3.175%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aura Biosciences Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (170.92% Upside)
$19.75 (170.92% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 83.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.69%
12-Months-Change
Fundamentals
Return on Equity
-78.12%
Trailing 12-Months
Asset Growth
-11.41%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
AURA Stock 12 Month Forecast
Average Price Target
$19.75
▲(170.92% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
3.02% Insiders
5.21% Mutual Funds
33.38% Other Institutional Investors
53.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---